Management of pressure ulcers.
OBJECTIVE
Wound healing, the epidemiology and staging of pressure ulcers, and pressure ulcer prevention and treatment are discussed.


CONCLUSIONS
The principal event leading to the formation of pressure ulcers appears to be a consistent interruption in blood supply to the skin. Several known risk factors exist and can be attributed to patient-specific variables and wound-specific conditions. Initial management should include removal of the source of pressure, a comprehensive assessment of the patient, and proper staging of the ulcer. Preparation of the wound for treatment is essential and can have a significant impact on healing. While the patient's nutritional status is thought to affect wound healing, only an increased protein content in the diet has been demonstrated to have a benefit. Specialized wound dressings are available for pressure ulcers of all stages and drainage characteristics. With wide variation in cost and in application regimens, a direct cost-effectiveness comparison of commercially available dressing products is difficult. Many of the growth factors commonly present in healing wounds have been synthesized and evaluated as treatments. Although topical platelet-derived growth factor has demonstrated benefit in some studies, its use remains controversial. To date, no topical growth factors carry FDA-approved labeling for use in the treatment of pressure ulcers. Human skin equivalents mark the latest advancement in therapy. Certain species of bacteria have been associated with poorly healing ulcers and may warrant intervention with either local or systemic antibiotic therapy.


CONCLUSIONS
No pharmacologic intervention has been conclusively shown to be effective for pressure ulcers. The cornerstones of therapy remain elimination of the source of pressure or friction and appropriate wound care. usa.
Department of Pharmacy Practice, College of Pharmacy, University of Illinois at Chicago, 60612, USA. bcannon@uic.edu
Bradley C
BC
Cannon
Joan P
JP
Cannon
D000890:Anti-Infective Agents / Q000627:therapeutic use*; D001458:Bandages / Q000009:adverse effects; D003646:Debridement; D006801:Humans; D003668:Pressure Ulcer / Q000191:economics / Q000473:pathology / Q000628:therapy; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D014945:Wound Healing
D000890:Anti-Infective Agents